2015-09-23 18:32:32 UTC

New CRC Drug Gets Go Ahead from FDA

Sept. 24, 2015

Lonsurf is taken orally and designed to treat CRC in patients who have previously been treated with chemotherapy and biologic therapy.

FDA has approved a new therapy that aims to treat advanced CRC in patients who have previously been treated with chemotherapy and biologic therapy. The drug, Lonsurf, combines both trifluridine and tipiracil in pill form.

During the double-blind study of Lonsurf, patients treated with the drug "lived an average of 7.1 months compared to 5.3 months for those treated with placebo," according to FDA, which also noted that "on average, the time to disease progression was two months for patients on Lonsurf compared to 1.7 months for patients receiving placebo."

FDA, which made the announcement on Sept. 22, advises health-care providers to strictly monitor patients during Lonsurf therapy, and recommends that they obtain complete blood counts of patients before each treatment cycle due to possible myelosuppression. Providers should also advise female patients on potential side effects of the drug on pregnancy. Lonsurf is manufactured by Taiho Oncology Inc.

For more information, review the AGA Colorectal Cancer Clinical Service Line, which was created through the AGA Roadmap to the Future of GI Practice, to support high-quality patient care.

More on Colonoscopy

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Choose from 30 breakout sessions at the 2018 AGA Postgraduate Course

March 21, 2018

Delve deeper into specific clinical topics that interest you and get concrete action items that can be immediately implemented into your practice.

Ready for the “Jimmy Kimmel effect”?

March 21, 2018

AGA leader Dr. Christina Ha performed Jimmy Kimmel’s first colonoscopy. Here’s the clip.